{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:02Z","timestamp":1790665622687,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,10,15]]},"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) cells develop chemo-resistance over time. Most anticancer agents function through induction of apoptosis, and therefore resistance against these agents is likely to be caused by selection for CLL cells with defects in the particular apoptosis pathway that is triggered by these drugs. Anticancer agents that function through alternative apoptotic pathways might therefore be useful in treating chemo-resistant CLL. Triterpenoids represent a class of naturally occurring and synthetic compounds with demonstrated antitumor activity. We examined the effects of CDDO (triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid) on CLL B cells in vitro. CDDO induced apoptosis in a dose-dependent manner in all (n\u2009=\u200930) CLL samples tested, including previously untreated and chemo-resistant CLL specimens. CDDO induced rapid proteolytic processing of caspase-8, but not caspase-9, in CLL B cells, suggesting activation of a mitochondria-independent pathway. CDDO-induced apoptosis of CLL B cells was blocked by cytokine response modifier A (CrmA), a suppressor of caspase-8, but not by X-linked inhibitor of apoptosis protein\u2013baculovirus IAP repeat\u20133 (XIAP-BIR3), a fragment of XIAP, which selectively inhibits caspase-9. Examination of CDDO effects on expression of several apoptosis-relevant genes demonstrated significant reductions in the levels of caspase-8 homolog Fas-ligand interleukin-1\u2013converting enzyme (FLICE)\u2013inhibitory protein (c-FLIP), an endogenous antagonist of caspase-8. However, reductions of FLIP achieved by FLIP antisense oligonucleotides were insufficient for triggering apoptosis, indicating that CDDO has other targets in CLL B cells besides FLIP. These data suggest that the synthetic triterpenoid CDDO should be further explored as a possible therapeutic agent for treatment of chemo-resistant CLL.<\/jats:p>","DOI":"10.1182\/blood-2002-04-1174","type":"journal-article","created":{"date-parts":[[2002,9,26]],"date-time":"2002-09-26T19:44:31Z","timestamp":1033069471000},"page":"2965-2972","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":143,"title":["The triterpenoid CDDO induces apoptosis in refractory CLL B cells"],"prefix":"10.1182","volume":"100","author":[{"given":"Irene M.","family":"Pedersen","sequence":"first","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kitada","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Schimmer","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Zapata","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lula","family":"Charboneau","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rassenti","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bennett","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Sporn","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance D.","family":"Liotta","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Reed","sequence":"additional","affiliation":[{"name":"From The Burnham Institute and University of California\u2013San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111821461881700_B1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.47.1.5","article-title":"Cancer statistics.","volume":"47","author":"Parker","year":"1997","journal-title":"CA Cancer J Clin."},{"key":"2019111821461881700_B2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd726","article-title":"Apoptosis-based therapies.","volume":"1","author":"Reed","year":"2002","journal-title":"Nat Drug Disc."},{"key":"2019111821461881700_B3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0092-8674(00)81728-6","article-title":"Apoptotic pathways: the roads to ruin.","volume":"94","author":"Green","year":"1998","journal-title":"Cell."},{"key":"2019111821461881700_B4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0092-8674(00)80430-4","article-title":"Caspases: intracellular signaling by proteolysis.","volume":"91","author":"Salvesen","year":"1997","journal-title":"Cell."},{"key":"2019111821461881700_B5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/74994","article-title":"Mitochondrial control of cell death.","volume":"6","author":"Kroemer","year":"2000","journal-title":"Nat Med."},{"key":"2019111821461881700_B6","doi-asserted-by":"crossref","first-page":"10964","DOI":"10.1073\/pnas.96.20.10964","article-title":"Caspase activation: the induced-proximity model.","volume":"96","author":"Salvesen","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821461881700_B7","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1126\/science.281.5381.1312","article-title":"Caspases: enemies within.","volume":"281","author":"Thornberry","year":"1998","journal-title":"Science."},{"key":"2019111821461881700_B8","first-page":"1227","article-title":"Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.","volume":"9","author":"Panayiotidis","year":"1995","journal-title":"Leukemia."},{"key":"2019111821461881700_B9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2141.1997.422688.x","article-title":"Role of the CD40 and CD95 (APO-1\/Fas) antigens in the apoptosis of human B-cell malignancies.","volume":"97","author":"Wang","year":"1997","journal-title":"Br J Haematol."},{"key":"2019111821461881700_B10","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.V98.9.2800","article-title":"Caspase 8 activation independent of Fas (CD95\/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or \u03b3 radiation.","volume":"98","author":"Jones","year":"2001","journal-title":"Blood."},{"key":"2019111821461881700_B11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1365-2141.1997.4393250.x","article-title":"Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies.","volume":"99","author":"Snell","year":"1997","journal-title":"Br J Haematol."},{"key":"2019111821461881700_B12","first-page":"1550","article-title":"A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor \u03b3.","volume":"14","author":"Wang","year":"2000","journal-title":"Mol Endocrinol."},{"key":"2019111821461881700_B13","doi-asserted-by":"crossref","first-page":"16448","DOI":"10.1074\/jbc.M108974200","article-title":"The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells.","volume":"277","author":"Stadheim","year":"2002","journal-title":"J Biol Chem."},{"key":"2019111821461881700_B14","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1021\/jm000008j","article-title":"Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages.","volume":"43","author":"Honda","year":"2000","journal-title":"J Med Chem."},{"key":"2019111821461881700_B15","first-page":"717","article-title":"Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages.","volume":"58","author":"Suh","year":"1998","journal-title":"Cancer Res."},{"key":"2019111821461881700_B16","first-page":"261","article-title":"The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism.","volume":"11","author":"Ito","year":"2000","journal-title":"Cell Growth Differ."},{"key":"2019111821461881700_B17","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/mol.59.5.1094","article-title":"The novel triterpenoid CDDO induced apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism.","volume":"59","author":"Ito","year":"2001","journal-title":"Mol Pharmacol."},{"key":"2019111821461881700_B18","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood."},{"key":"2019111821461881700_B19","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/S0960-894X(98)00479-X","article-title":"Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide producion in mouse macrophages.","volume":"8","author":"Honda","year":"1998","journal-title":"Bioorg Med Chem Lett."},{"key":"2019111821461881700_B20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0076-6879(00)22014-4","article-title":"Viral caspase inhibitors CrmA and p53.","volume":"322","author":"Zhou","year":"2000","journal-title":"Methods Enzymol."},{"key":"2019111821461881700_B21","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.1074\/jbc.273.14.7787","article-title":"A single BIR domain of XIAP sufficient for inhibiting caspases.","volume":"273","author":"Takahashi","year":"1998","journal-title":"J Biol Chem."},{"key":"2019111821461881700_B22","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1093\/emboj\/18.19.5242","article-title":"Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases.","volume":"18","author":"Deveraux","year":"1999","journal-title":"EMBO J."},{"key":"2019111821461881700_B23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0092-8674(00)80085-9","article-title":"Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.","volume":"86","author":"Liu","year":"1996","journal-title":"Cell."},{"key":"2019111821461881700_B24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/40901","article-title":"X-linked IAP is a direct inhibitor of cell death proteases.","volume":"388","author":"Deveraux","year":"1997","journal-title":"Nature."},{"key":"2019111821461881700_B25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/abio.1996.0160","article-title":"Detection of multiple antigens on Western blots.","volume":"236","author":"Krajewski","year":"1996","journal-title":"Anal Biochem."},{"key":"2019111821461881700_B26","doi-asserted-by":"crossref","first-page":"26953","DOI":"10.1074\/jbc.272.43.26953","article-title":"FLICE is predominantly expressed as two functionally active isoforms, caspase-8\/a and caspase-8\/b.","volume":"272","author":"Scaffidi","year":"1997","journal-title":"J Biol Chem."},{"key":"2019111821461881700_B27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/40657","article-title":"Inhibition of death receptor signals by cellular FLIP.","volume":"388","author":"Irmler","year":"1997","journal-title":"Nature."},{"key":"2019111821461881700_B28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1471-4914(01)02100-1","article-title":"Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs).","volume":"7","author":"Sporn","year":"2001","journal-title":"Trends Mol Med."},{"key":"2019111821461881700_B29","first-page":"3","article-title":"Molecular biology of chronic lymphocytic leukemia: implications for therapy.","volume":"35","author":"Reed","year":"1998","journal-title":"Semin Hematol."},{"key":"2019111821461881700_B30","first-page":"S67","article-title":"Pharmacology of purine nucleoside analogues.","volume":"38(suppl2)","author":"Plunkett","year":"1996","journal-title":"Hematol Cell Ther."},{"key":"2019111821461881700_B31","first-page":"336","article-title":"A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.","volume":"59","author":"Suh","year":"1999","journal-title":"Cancer Res."},{"key":"2019111821461881700_B32","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/2030","article-title":"Differentiation and reversal of malignant changes in colon cancer through PPAR\u03b3.","volume":"4","author":"Sarraf","year":"1998","journal-title":"Nat Med."},{"key":"2019111821461881700_B33","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","article-title":"Ligands for peroxisome proliferator-activated receptor\u03b3 and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.","volume":"95","author":"Elstner","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821461881700_B34","doi-asserted-by":"crossref","first-page":"22320","DOI":"10.1074\/jbc.M202458200","article-title":"An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis.","volume":"277","author":"Kim","year":"2002","journal-title":"J Biol Chem."},{"key":"2019111821461881700_B35","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537.h8003537_3537_3543","article-title":"Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.","volume":"96","author":"Genini","year":"2000","journal-title":"Blood."},{"key":"2019111821461881700_B36","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood.V98.9.2603","article-title":"Cellular stress response and apoptosis in cancer therapy.","volume":"98","author":"Herr","year":"2001","journal-title":"Blood."},{"key":"2019111821461881700_B37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0092-8674(00)81477-4","article-title":"Differential requirement for caspase 9 in apoptotic pathways in vivo.","volume":"94","author":"Hakem","year":"1998","journal-title":"Cell."},{"key":"2019111821461881700_B38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0092-8674(00)81476-2","article-title":"Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9.","volume":"94","author":"Kuida","year":"1998","journal-title":"Cell."},{"key":"2019111821461881700_B39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(00)81732-8","article-title":"Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development.","volume":"94","author":"Cecconi","year":"1998","journal-title":"Cell."},{"key":"2019111821461881700_B40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0092-8674(00)81733-X","article-title":"Apaf1 is required for mitochondrial pathways of apoptosis and brain development.","volume":"94","author":"Yoshida","year":"1998","journal-title":"Cell."},{"key":"2019111821461881700_B41","doi-asserted-by":"crossref","first-page":"9303","DOI":"10.1074\/jbc.275.13.9303","article-title":"Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis.","volume":"275","author":"Tang","year":"2000","journal-title":"J Biol Chem."},{"key":"2019111821461881700_B42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0952-7915(98)80223-9","article-title":"Inhibition of Fas death signals by FLIPs.","volume":"10","author":"Tschopp","year":"1998","journal-title":"Curr Opin Immunol."},{"key":"2019111821461881700_B43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0031-6865(99)00038-2","article-title":"Apoptosis induced by death receptors.","volume":"74","author":"Schneider","year":"2000","journal-title":"Pharm Acta Helv."},{"key":"2019111821461881700_B44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V99.1.326","article-title":"Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.","volume":"99","author":"Konopleva","year":"2002","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/8\/2965\/1259304\/h82002002965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/8\/2965\/1259304\/h82002002965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T21:46:35Z","timestamp":1574113595000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/8\/2965\/106473\/The-triterpenoid-CDDO-induces-apoptosis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,15]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-04-1174","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10,15]]}}}